Drugs / Hemay5087
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07624864 | Jul 2026 → Apr 2028 expected | cancer | Ganzhou Hemay Pharmaceutical Co., Ltd | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hemay5087 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07624864 ↗ |
| Route | Intravenous | “intravenous infusion，once every 3 weeks” NCT07624864 ↗ |